Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Raw Materials (2016 - 2019)

Plus Therapeutics (PSTV) has disclosed Raw Materials for 9 consecutive years, with $663000.0 as the latest value for Q1 2019.

  • Quarterly Raw Materials fell 4.6% to $663000.0 in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $663000.0 through Mar 2019, down 4.6% year-over-year, with the annual reading at $758000.0 for FY2018, 11.31% up from the prior year.
  • Raw Materials for Q1 2019 was $663000.0 at Plus Therapeutics, down from $758000.0 in the prior quarter.
  • The five-year high for Raw Materials was $1.7 million in Q1 2015, with the low at $663000.0 in Q1 2019.
  • Average Raw Materials over 5 years is $1.0 million, with a median of $907000.0 recorded in 2017.
  • The sharpest move saw Raw Materials surged 56.58% in 2017, then crashed 53.81% in 2018.
  • Over 5 years, Raw Materials stood at $1.0 million in 2015, then dropped by 12.29% to $885000.0 in 2016, then fell by 23.05% to $681000.0 in 2017, then grew by 11.31% to $758000.0 in 2018, then dropped by 12.53% to $663000.0 in 2019.
  • According to Business Quant data, Raw Materials over the past three periods came in at $663000.0, $758000.0, and $698000.0 for Q1 2019, Q4 2018, and Q3 2018 respectively.